Differentiation-dependent telomeric long non-coding transcription in a model of skeletal myogenesis

Scott W Brouilette1*, Samir Ounzain2*, Vinit Sawhney1, Kenta Yashiro1, Yasunori Shintani1, Kunihiko Takahashi1, Steven R Coppen1, Takuya Narita1, Kelli Torsney1, Martin Carrier1, Niall Campbell1, Ken Suzuki1.

*Equal contributors and corresponding authors

1Translational Cardiovascular Therapeutics
William Harvey Research Institute
Barts and The London School of Medicine
Queen Mary University of London
EC1M 6BQ
United Kingdom

2Experimental Cardiology Unit
University of Lausanne Medical School
Experimental Cardiology Unit
Rue du Bugon 27
CH-1005 Lausanne
Switzerland

Corresponding authors:

Scott W. Brouilette
Tel: +44 (0) 20 7882 8237
Fax: +44 (0) 20 7882 8252
s.w.brouilette@qmul.ac.uk

Samir Ounzain
Tel: +41 (0) 21 6925 367
Fax: +41 (0) 21 3145 978
samir.ounzain@chuv.ch
Abstract

Telomeres comprise the distal ends of eukaryotic chromosomes, serve to maintain genomic integrity and are extended by the ribonucleoprotein telomerase. Recent evidence indicates that telomeres are transcribed to generate long non-coding RNAs (lncRNAs) and that these transcripts (TERRA) may inhibit telomerase activity. In this study we assessed telomerase activity and telomeric lncRNA expression in a mouse model of skeletal myogenesis. Using the C2C12 cell line we demonstrated decreased telomerase activity during differentiation into terminally-differentiated skeletal myotubes. Despite existing in a post-mitotic state, residual telomerase activity remained in C2C12 myotubes, indicating a role independent of telomere extension. Telomeric transcripts were detected in both myoblasts and myotubes, with reduced expression during differentiation correlating with reduced telomerase expression. Our data indicate that in a mouse model of skeletal myogenesis TERRA expression does not reduce telomerase activity, suggesting that their relationship is more complex than originally perceived; the role of telomeric derived lncRNAs in relation to telomerase activity may be cell-type specific. These findings raise the possibility for novel non-telomerase regulatory function for TERRA-lncRNAs during skeletal myogenesis.

Keywords: telomere; telomerase; long non coding RNA; TERRA; differentiation; skeletal; myogenesis.
Introduction

Telomeres comprise the distal ends of eukaryotic chromosomes and consist of a highly conserved, repetitive sequence up to 150 kilobases (kb) in certain mouse strains (Kipling & Cooke 1990; Starling et al. 1990; Zijlmans et al. 1997). Although the full complement of telomeric functions remains to be determined, increasing evidence supports roles in maintenance of genomic integrity (Chan & Blackburn 2004). A region of telomeric DNA fails to be replicated during cell division, resulting in progressive telomere shortening. The ribonucleoprotein, telomerase, is capable of extending telomeres (Greider & Blackburn 1985), but while telomerase is generally active in germ and progenitor cells, its activity is repressed in human somatic and differentiated cells (Wright et al. 1996). In contrast, tissue specific expression has been reported in somatic/differentiated cells from mouse models (Prowse & Greider 1995). Recent reports indicate that rather than being inert structures, telomeric C-rich tracts are actively transcribed by RNA polymerase II (Azzalin et al. 2007), giving rise to telomere derived long non coding RNAs (lncRNAs) called TERRA. The phenomenon appears to be regulated by developmental status, telomere length, cellular stress and chromatin structure (Schoeftner & Blasco 2008). Furthermore, TERRA has been shown to block telomerase activity in both mouse embryonic stem cells, and the HeLa cell line (Schoeftner & Blasco 2008), raising the possibility that one function of TERRA is to provide a method of fine control of telomerase activity during growth and development. Additionally, TERRA may also act as a regulator of telomeric heterochromatin, analogous to other lncRNAs including HOTAIR and Xist (Luke & Lingner 2009).

Development of skeletal muscle is mediated by a coordinated series of events, beginning with commitment of mesodermal precursor cells to the skeletal muscle lineage followed by myoblast fusion and alterations in muscle-specific gene expression (Buckingham et al. 2003;
Christ & Ordahl 1995; McKinsey et al. 2002), including MyoD for myoblast specification (Andres & Walsh 1996; Dedieu et al. 2002). Terminal differentiation is characterised by exit from the cell cycle, and telomerase down-regulation is considered to be an early, necessary step in the process. In light of this we set out to assess telomere, telomerase and TERRA IncRNA dynamics in a mouse model of skeletal myogenesis.
Results:

**Skeletal myogenesis**

Reduction of serum concentration as cells approached confluence resulted in classic myoblast (MB) fusion followed by multi-nucleation by day 2 (2dMT), becoming more pronounced by day 4 (4dMT, Figure 1a). It has been reported that proliferating myoblasts exit the cell cycle when MyoD is at its highest level (Skapek et al. 1995) and consistent with this we observed the highest level of expression in proliferating MBs with a 48.5% reduction in expression at day 4 of differentiation (p<0.05, Figure 1b). During differentiation we also observed an 83% reduction (p<0.001) in the key cell cycle regulator, cyclin D1 at day 4 (Figure 1b). This down-regulation is critical for myogenesis as cyclin D1 is capable of inhibiting the ability of MyoD to transactivate muscle-specific genes (Skapek et al. 1995), including Mef2c (Dodou et al. 2003), transcription of which was consequently increased 148% (p<0.05) in 2dMT (Figure 1c). Myocyte stress 1 (MS1) is a recently identified downstream target of MyoD shown to play a key role in C2C12 differentiation (Ounzain et al. 2008). Consistent with this Ms1 transcription increased 129% in 2dMT (p<0.05) and 341% in 4dMT (p<0.05, Figure 1c). Finally, Creatine kinase M isozyme (CKM) transcript increased 123% in 4dMT (p<0.01), consistent with previous reports (Ito et al. 2005).

**Telomerase activity is decreased, but not absent, in C2C12 myotubes**

Skeletal myogenesis is characterised by skeletal myoblast fusion to yield terminally-differentiated myotubes, while terminal differentiation itself is characterised by exit from the cell cycle. The ribo-nucleoprotein telomerase is capable of extending telomeres and expression is reported to occur during S-phase of the cell cycle (Zhao et al. 2008), thus activity is expected to diminish upon terminal differentiation. Figure 2a demonstrates telomerase activity in proliferating myotubes, with a 46% reduction in 2dMT and 59% in
4dMT (p<0.001 in both cases compared to MB). Thus, in contrast to previous reports (Bestilny et al. 1996; Holt et al. 1996) residual telomerase activity remained upon terminal differentiation.

**Telomere length**

Figure 2b demonstrates that telomere length, measured by pulse field gel electrophoresis, was similar between groups (25.4±0.17kb in MB and 26.9±0.58kb in 4dMT, p=0.1538).

**TERRA is expressed in both C2C12 myoblasts and myotubes**

To assess proliferating and differentiated C2C12 cells for TERRA expression we used two independent methods. RNA-FISH revealed TERRA expression in 92.5±5.8% of proliferating MBs. This was significantly reduced to 40.7±13.2% in 2dMT and 35.8±13.5% in 4dMT (p<0.001 in both cases compared to MB, Figure 3a). Consistent with this, RNA dot-blotting indicated a 51% reduction in TERRA expression between proliferating MB and 4dMT (p=0.017, Figure 3b).

**Abrogation of telomerase activity by synthetic TERRA**

TERRA possesses complimentary to the RNA template of the telomerase complex, and has been shown to inhibit telomerase activity in the TRAP assay (Schoeftner & Blasco 2008). To assess the impact of TERRA on telomerase activity in our model protein extracts were incubated with increasing amounts of the synthetic TERRA oligonucleotide, T1 ([UUAGGG]₃), prior to the assay. Addition of T1 resulted in a significant reduction in telomerase activity at all concentrations tested (over 90%, p<0.01 in all cases, Figure 4).
Discussion

In the present study we have characterised the changes in telomerase activity and TERRA IncRNA expression that occur during the differentiation of the mouse C2C12 cell line from proliferating myoblasts to terminally-differentiated myotubes. In contrast to reports indicating almost complete abrogation of telomerase activity during myogenesis we report only a 50% reduction, indicating a role independent of telomere length maintenance in post-mitotic cells. Furthermore, telomeric transcripts (TERRA) were observed in both C2C12 myoblasts and myotubes, with reduced expression during myogenesis correlating with reduced telomerase activity. Given recent reports indicating that increased TERRA expression down-regulates telomerase activity (Ng et al. 2009; Schoeftner & Blasco 2008), our novel observation implies a complex relationship between TERRA and telomerase activity during skeletal myogenesis.

Our findings expand on the limited data relating to telomerase down-regulation in terminal differentiation during skeletal myogenesis. Unlike previous reports that indicate a greater than 90% down-regulation as the cells exit the cell cycle and differentiate into myotubes (Bestilny et al. 1996; Holt et al. 1996), we observed residual telomerase activity at relatively high levels (50% of the maximum in highly proliferative myoblasts). This may reflect technical differences between the methodologies, with the TRAP-ELISA reporting levels of activity that were previously below the threshold of detection using the original assay. While telomerase was originally thought to be superfluous in cells that had exited the cell cycle, there is recent evidence suggesting that telomerase may have functions that are independent of telomere length maintenance. During oxidative stress telomerase has been shown to be actively exported from the nucleus to the cytoplasm where it co-localises with mitochondria (Ahmed et al. 2008), preserving function by binding to mitochondrial DNA and protecting
against oxidative stress-induced damage (Haendeler et al. 2009). Proteomic analysis of C2C12 cells indicates that respiratory chain proteins are up-regulated by 10 days post-differentiation (Kislinger et al. 2005), resulting in increased potential for generation of oxidative stress. This is countered, in part, by up-regulation of uncoupling protein-3 (Flandin et al. 2005). Given that these data illustrate the importance of managing the increased oxidative stress that can be generated by differentiated skeletal muscle, our data indicating residual telomerase activity in post-mitotic cells suggests a potential role for telomerase, independent of its role in maintaining telomeric structure. This may represent a pre-emptive, protective mechanism, as the cell prepares itself to cope with the increased oxidative stress that may ensue as myotube formation is completed and muscle contraction begins.

The current model for TERRA regulation of telomerase activity proposes that TERRA anneals to the RNA sub-unit of telomerase, abrogating its use as a template for telomere extension (Schoeftner & Blasco 2008), however our data demonstrating a significant reduction in TERRA expression during differentiation, concurrent with reduced telomerase activity, suggest an alternative relationship during myogenesis. While we report a positive correlation between TERRA and telomerase activity in the cell model we did observe a negative correlation in an in vitro assay of telomerase activity, indicating that TERRA does indeed inhibit telomerase activity when simply incubated with protein extracts from the C2C12 cell line. One potential explanation for our observed changes in TERRA during C2C12 differentiation relates to SMG proteins, several of which are involved in telomere maintenance. Upf1 in particular is up-regulated over 5-fold during myogenesis in C2C12 cells (Kim et al. 2007), and Azzalin et al (Azzalin et al. 2007) have shown that Upf1 promotes the displacement of TERRA from telomeric chromatin. TERRA appears to be under tight transcriptional control (Schoeftner & Blasco 2008); while telomere-associated TERRA may
promote genomic stability (Horard & Gilson 2008), detachment likely leads to degradation. This model would be consistent with our data: telomeric transcription may remain high in myotubes (or may actually increase in an attempt to fine-tune down-regulation of telomerase activity), but the increased Upf1 reported in C2C12 myotubes may displace TERRA resulting in rapid degradation, thus we observed a reduced signal.

A second mechanism involving methylation may also play a role. Methylation is an epigenetic mechanism that generally results in silencing of the associated sequence. In humans sub-telomeric DNA is hypo-methylated in sperm and ova, and is subjected to heavy de novo methylation during development (Brock et al. 1999; de Lange et al. 1990). Recently it has been demonstrated that disease-associated hypo-methylation of the sub-telomere in humans is accompanied by increased TERRA (Yehezkel et al. 2008); rather than a primary role in telomerase regulation, TERRA formation may reflect altered epigenetic status at the sub-telomeric region. Importantly, the two mechanisms outlined are not mutually exclusive.

Finally, it is also possible that during myogenic differentiation TERRA mediates an exclusively non-telomerase/telomeric functional role. Considering the increasingly vast repertoire of regulatory functions encoded by long non coding RNAs we suspect TERRA function could be diverse and cell-type/context specific (Wang & Chang 2011; Wapinski & Chang 2011). To conclude, we provide the first report of telomeric lncRNA expression in a mouse model of skeletal myogenesis, and demonstrate a positive association with telomerase activity. These data are in contrast to previous reports, albeit using different cell types, suggesting that TERRA inhibits telomerase activity, and indicate that the relationship may be cell-type specific and, thus, more complex than originally believed. Importantly, this study raises several questions regarding the relationship between TERRA expression and telomerase activity during skeletal myogenesis.
Experimental Procedures

Cell culture

C2C12 mouse skeletal myoblasts were cultured in DMEM (Invitrogen) supplemented with 20% fetal calf serum, 2mM glutamine, penicillin (100 units/ml, Sigma) and streptomycin (100µg/ml, Sigma) and maintained at 37°C in 5% CO₂. Once cells exceeded 90% confluence media was replaced with DMEM supplemented with 2% horse serum to induce differentiation. Differentiation media was changed every 2 days.

Morphology and myotube formation

For assessment of myogenic differentiation, C2C12 cells were cultured in chamber slides and examined as proliferating myoblasts (MB), 2 day (2dMT) and 4 day myotubes (4dMT). For assessment of cellular fusion media was aspirated and replaced with fresh media containing Vybrant Cell Labeling Solution (Invitrogen) at 1:200 dilution and incubated at 37°C for 20 minutes, followed by three 10 minute washes in fresh, unlabeled media. After washing in phosphate-buffered saline (PBS), cells were fixed in 4% paraformaldehyde for 10 minutes, washed in 70% ethanol and mounted (Dako Fluorescent Mount containing 200ng/ml 4’,6-diamidino-2-phenylindole (DAPI) counter-stain). Images were captured on a Keyance All-In-One Fluorescent microscope (Keyance, Japan).

Western blotting

Total protein was isolated using SB₂₀ buffer (50mM Tris pH 7.4, 5mM EDTA, 20% SDS), quantititated using BioRad DC Protein Assay (BioRad), electrophoresed in SDS-polyacrylamide gels (Invitrogen) and transferred to Hybond ECL (GE Healthcare). Membranes were probed with antibodies against MyoD (Santa Cruz) and Cyclin D1 (Millipore), normalized to α-tubulin (Sigma). Autoradiographs were scanned and image

RNA isolation

Cells were trypsinized and total RNA was isolated using the RNeasy Mini Kit (QIAgen) according to manufacturer’s guidelines. On-column DNase I digestion (RNase-Free DNase Set, QIAgen) was performed to eliminate genomic DNA contamination.

RT-PCR

Total RNA (2μg) was reverse transcribed to cDNA using oligo (dT) and Superscript II Reverse Transcriptase (Invitrogen) according to the manufacturers instructions. Quantitative PCR (QPCR) was executed using a 7500 Real-Time PCR System (Applied Biosystems). Briefly, a master-mix containing (per reaction) 12.5μl SYBR-Green Jump Start Taq Readymix (Sigma-Aldrich) and 5μl oligonucleotides (5pmol of forward and reverse primers) were aliquoted into Optical 96-well reaction plates (Applied Biosystems), and the cDNA template added (7.5μl, 1/15 dilution in ddH2O). PCR cycling parameters for all primer pairs were 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 59°C for 60 seconds. Subsequent to QPCR, a dissociation curve analysis was performed to check for aberrant amplification products. QPCR analysis of Gapdh was performed in each 96-well plate as an endogenous control and the relative quantitation protocol was used. Primers for QPCR were as follows: Gapdh: forward 5’-ACC ACA GTC CAT GCC ATC AC-3’, reverse 5’-TCC ACC ACC CTG TTG CTG TA-3’; Ckm: forward 5’-TCA AGG GTT ACA CTC TGC CT-3’, reverse 5’-TTC ACC ACC CAC ACA AGG AAG C-3’; Mef2c: forward 5’-ATT CCT GCT GTT CCT TCA C-3’, reverse 5’-AAC GCG GAG ATC TGG CTT AC-3’; Ms1: forward 5’-GTG ACA GCA TAG ACA CAG GAG GAC-3’. reverse 5’-CAC TGC TGC CCA CCT GCC TT-3’. All samples run in duplicate.
**Telomerase Activity**

Telomerase activity was assessed using TeloTAGGG Telomerase PCR ELISA (Roche) according to manufacturer’s instructions. Briefly, at each time-point 2x10⁵ cells were washed in PBS, pelleted and lysed to release protein. Samples were assayed in duplicate, using 5000 cell equivalents per PCR reaction, and 5μl of PCR product per ELISA. HeLa cells were used as a positive control; heat inactivated samples (10 minutes at 85°C prior to PCR) served as negative controls.

**Telomere Length**

Telomere length was assessed using pulse-field gel electrophoresis (PFGE). Briefly, at each time-point cells were harvested and 10⁷ cells embedded in agarose gel plugs (CHEF Genomic DNA Plug Kit, BioRad) and digested with RsaI/HinfI (Invitrogen). Gel plug pieces containing approximately 2x10⁶ cells were subjected to PFGE, transferred to Hybond N⁺ (GE Healthcare) and telomeric signals visualized using TeloTAGGG Telomere Length Assay (Roche). Autoradiographs were scanned and image analysis performed using ImageQuant (Molecular Dynamics), as previously described (Brouilette et al. 2003; Vasa-Nicotera et al. 2005).

**RNA-Fluorescence in situ hybridization (FISH)**

RNA-FISH was performed as previously described (Azzalin et al. 2007). Briefly, cells were cultured in chamber-slides (Nunc) until reaching required degree of confluency/differentiation. Slides were washed in PBS and incubated for 7 minutes in ice-cold cyto-skeletal (CSK) Buffer (100mM NaCl, 300mM sucrose, 3mM MgCl₂, 10mM PIPES pH 7.0, 0.5% Triton-X) containing either 10mM Vanadyl Ribonucleoside Complex
(New England Biolabs) or 1mg/ml Rnase A (Invitrogen). Slides were washed again in PBS, fixed in 4% paraformaldehyde for 10 minutes at room temperature, and dehydrated in an ethanol series (70%, 90% and 100%, 5 minutes each). After air-drying slides were hybridised (2x SSC, 2mg/ml BSA, 10% dextran sulphate, 20% formamide, 2.0ug/ml PNA-telomere probe, 10mM Vanadyl Ribonucleoside Complex) overnight at 37°C. Slides were then washed twice with 2X SSC/50% formamide at 37°C, twice with 2X SSC at 37°C, and once with 2X SSC at room temperature. Slides were mounted with fluorescent mounting media (Dako) and DAPI counterstain (200ng/ml). Images were captured using a Keyance All-In-One Fluorescent microscope (Keyance, Japan) using 40x magnification and identical settings for both myoblast and myotube slides (9 second exposure time in Cy-5 channel for TERRA). TERRA formation was quantitated as percentage of TERRA positive DAPI-stained nuclei per field (7-10 random fields per time-point).

**RNA dot-blot**

Total RNA (5μg) was spotted in duplicate onto Hybond N+ (GE Healthcare) with RNase A treated samples included as controls. Blots were air-dried, UV cross-linked using the Autocrosslink Mode (Stratagene) and pre-hybridised for 1 hour at 55°C in Easy Hyb solution (Roche). 100pmol telomere probe (CCCTAA)₃ was labeled with DIG using DIG Oligonucleotide 3’-End-Labeling Kit (Roche) and hybridised overnight at 55°C. Following low stringency (2xSSC/0.1% SDS at room temperature) and high stringency (0.2xSSC/0.1% SDS at 55°C) washes, blots were visualised using the DIG Northern Starter Kit (Roche). Blots were stripped and re-probed with Gapdh as control. Autoradiographs were scanned and image analysis performed using ImageJ (ImageJ: [http://rsb.info.nih.gov/ij](http://rsb.info.nih.gov/ij)).

**Synthetic TERRA**
Protein lysates (5000 cell equivalents) from C2C12 myoblasts were incubated with increasing amounts (2, 10 and 50 pmoles) of T1 ([UUAGGG]₃) oligonucleotide (50μl total reaction volume) prior to the telomerase extension reaction in Telomerase PCR ELISA.

Statistical Analysis

Differences in percentage of TERRA foci per field (FISH), TERRA expression (RNA dot-blot) and telomerase activity (TRAP-ELISA) at each time point were compared by one-way ANOVA and Bonferroni’s Multiple Comparison Test. A p-value <0.05 was considered significant.

All analyses were performed using GraphPad Prism software (Version 4, 2005).

Acknowledgements:

This work was supported by the Barts and The London Charity.
References


**Figure Legends:**

**Fig 1.** Skeletal myogenesis. a) C2C12 MBs showed classic morphology, beginning to form sporadic myotubes by 2dMT and becoming more pronounced by 4dMT. Vybrant staining of the cell membranes along with DAPI counter-staining of nuclei illustrated the transition from single nuclei myoblasts to multi-nuclear myotubes by day 4. Scale bar = 50μm. b) Western blotting demonstrated a progressive decrease in myoblast-specific MyoD expression during differentiation. The cell-cycle regulator Cyclin D1 was also significantly reduced as myoblasts differentiated into myotubes. c) RT-PCR analysis revealed increases in transcript levels of Ms1, Mef2c and Ckm, all with reported roles in skeletal myogenesis. * p<0.05, ** p<0.01, *** p<0.001 vs MB.

**Fig 2.** Telomerase and telomere dynamics during myogenesis. a) Telomerase PCR ELISA demonstrated that, relative to proliferating MBs, telomerase activity was significantly reduced, although not completely abrogated, in 2dMTs and 4dMTs. b) Telomere length, measured by Pulse Field Gel Electrophoresis, showed no significant change during myogenesis. *** p<0.001 vs MB.

**Fig 3.** TERRA expression during myogenesis. a) RNA-FISH using a Cy-3 conjugated PNA probe and DAPI counter-stain revealed the presence of discrete TERRA foci in skeletal myoblasts, located to the nucleus. The frequency of cell nuclei exhibiting such foci was significantly less in 2dMTs and 4dMTs. b) RNA dot-blotting confirmed the decrease in TERRA during myogenesis. * p<0.05, *** p<0.001 vs myoblast. Scale bar = 50μm.
**Fig 4.** Telomerase inhibition by TERRA. Addition of synthetic TERRA inhibited telomerase activity, assessed by TRAP PCR-ELISA, at all concentrations tested. Activity was reduced in excess of 90%. **p<0.01 vs control (no TERRA).**